Eli Lilly Shares Surge Post-FDA Approval for Zepbound
Eli Lilly's stock soared following FDA approval of Zepbound, a novel weight-loss treatment for sleep apnea, boosting its position in the healthcare sector.
Eli Lilly shares gained after FDA approval for Zepbound, a weight-loss treatment for sleep apnea.